We are live on ! Find out more
SC

Scholtz & Company Portfolio holdings

AUM $195M
1-Year Est. Return 12.04%
This Fund
S&P 500
This Quarter Est. Return
+5.09%
1 Year Est. Return
+12.04%
3 Year Est. Return
+82.55%
5 Year Est. Return
+94.25%
10 Year Est. Return
+790.35%
AUM
$235M
AUM Growth
+$8.28M
Cap. Flow
-$1.46M
Cap. Flow %
-0.62%
Top 10 Hldgs %
55.29%
Holding
56
New
6
Increased
14
Reduced
27
Closed
6

Top Buys

Rank Stock Value
1
ABT icon
Abbott
ABT
+$3.57M
2
AMD icon
Advanced Micro Devices
AMD
+$3.27M
3
PODD icon
Insulet
PODD
+$1.65M
4
VCEL icon
Vericel Corp
VCEL
+$1.39M
5
LLY icon
Eli Lilly
LLY
+$1.39M

Sector Composition

Rank Sector Weight
1 Technology 27.12%
2 Healthcare 16.32%
3 Consumer Discretionary 13.62%
4 Financials 13.36%
5 Industrials 10.71%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
LIN icon
51
Linde
LIN
$236B
-685
Closed -$318K
NFLX icon
52
Netflix
NFLX
$307B
-3,400
Closed -$206K
WRB icon
53
W.R. Berkley
WRB
$28.1B
-14,265
Closed -$841K
SWAV
54
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
-21,672
Closed -$7.06M

Similar funds

Scholtz & Company's Q2 2024 Portfolio in Review

As of Q2 2024, Scholtz & Company held 56 positions worth $235M, up 3.7% from $227M the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Scholtz & Company's Q2 2024 filing shows 6 new, 14 increased, 27 reduced and 6 closed positions. Its largest new stake was Insulet: 9,151 shares worth $1.85M. The largest sale was Shockwave Medical, Inc. Common Stock, an estimated $7.06M.

By sector, the portfolio is most concentrated in Technology at 27% of assets, up from 26% a quarter earlier, followed by Healthcare and Consumer Discretionary.

  • Scholtz & Company's largest Q2 2024 buy was Insulet: 9,151 shares worth $1.85M.
  • Scholtz & Company added most to Abbott in Q2 2024, an estimated $3.57M increase.
  • Scholtz & Company's biggest Q2 2024 reduction was RCI Hospitality Holdings, cutting an estimated $3.37M.
  • Scholtz & Company fully exited Shockwave Medical, Inc. Common Stock in Q2 2024, selling an estimated $7.06M.
  • Scholtz & Company's ten largest holdings make up 55% of its $235M portfolio in Q2 2024.
  • Scholtz & Company opened 6 new positions and closed 6 in Q2 2024.
  • Scholtz & Company's portfolio value rose 3.7% quarter-over-quarter to $235M.

Based on Scholtz & Company's 13F filing for Q2 2024, filed 8 Aug 2024.